PT  - JOURNAL ARTICLE
AU  - Kanakarajan, Hemalatha
AU  - Baene, Wouter De
AU  - Hanssens, Patrick
AU  - Sitskoorn, Margriet
TI  - Predicting local control of brain metastases after stereotactic radiotherapy with clinical, radiomics and deep learning features
AID  - 10.1101/2024.05.13.24307241
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.05.13.24307241
4099  - http://medrxiv.org/content/early/2024/06/06/2024.05.13.24307241.short
4100  - http://medrxiv.org/content/early/2024/06/06/2024.05.13.24307241.full
AB  - Background and purpose Timely identification of local failure after stereotactic radiotherapy for brain metastases allows for treatment modifications, potentially improving outcomes. Previous studies showed that adding radiomics or Deep Learning (DL) features to clinical features increased Local Control (LC) prediction accuracy. However, no study has integrated radiomics, DL, and clinical features into machine learning algorithms to predict LC. We examined whether a model using all these features achieves better accuracy than models using only a subset.Materials and methods We collected pre-treatment brain MRIs and clinical data for 129 patients at the Gamma Knife Center of the Elisabeth-TweeSteden Hospital. Radiomics features (extracted using the Python radiomics feature extractor) and DL features (extracted using a 3D ResNet model) were combined with clinical features. Performance of a Random Forest classifier was compared across four models trained with: clinical features only; clinical and radiomics features; clinical and DL features; and clinical, radiomics, and DL features.Results The prediction model utilizing only clinical variables provided an Area Under the receiver operating characteristic Curve (AUC) of 0.82 and an accuracy of 75.6%. Adding radiomics features increased the AUC to 0.88 and accuracy to 83.3%, while adding DL features resulted in an AUC of 0.86 and accuracy of 78.3%. The best performance came from combining clinical, radiomics, and DL features, achieving an AUC of 0.89 and accuracy of 87%.Conclusion Integrating radiomics and DL features with clinical characteristics improves LC prediction after stereotactic radiotherapy for brain metastases. These findings demonstrate the potential for early outcome prediction, enabling timely treatment modifications to improve patient management.Clinical and Translational Impact Statement Our study holds great clinical value, as the increased prediction accuracy can lead to tailored and effective interventions, resulting in better outcomes for brain metastases patients treated with stereotactic radiotherapy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research is supported by KWF Kankerbestrijding and NWO Domain AES, as part of their joint strategic research programme: Technology for Oncology IL. The collaboration project is co-funded by the PPP Allowance made available by Health Holland, Top Sector Life Sciences & Health, to stimulate public-private partnerships.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ETZ science office and by the Ethics Review Board at Tilburg University.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data used for this study is available at ETZ and is accessible after approval from the ETZ Science office.